How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/metastatic-non-small-cell-lung-cancer.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Metastatic non-small cell lung cancer — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Metastatic non-small cell lung cancer (disease) competitive landscape: 5 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

5 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Metastatic non-small cell lung cancer, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Retevmo	SELPERCATINIB	Eli Lilly	Kinase Inhibitor [EPC]	Proto-oncogene tyrosine-protein kinase receptor Ret	2020-01-01
Tabrecta	CAPMATINIB	Novartis Pharm	Kinase Inhibitor	Hepatocyte growth factor receptor	2020-01-01
Gavreto	PRALSETINIB	Rigel Pharms	Kinase Inhibitor [EPC]	RET	2020-01-01
Tecentriq	atezolizumab	Roche	Programmed Death Receptor-1 Blocking Antibody [EPC]	Programmed cell death 1 ligand 1	2016-01-01
(CARBAMIDE®)	(CARBAMIDE®)	German University in Cairo		Cyclin-dependent kinase-like 5, Hepatocyte growth factor receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Eli Lilly · 1 drug in Metastatic non-small cell lung cancer
German University in Cairo · 1 drug in Metastatic non-small cell lung cancer
Novartis Pharm · 1 drug in Metastatic non-small cell lung cancer
Rigel Pharms · 1 drug in Metastatic non-small cell lung cancer
Roche · 1 drug in Metastatic non-small cell lung cancer

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Metastatic non-small cell lung cancer:

Cite this brief

Drug Landscape (2026). Metastatic non-small cell lung cancer — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/metastatic-non-small-cell-lung-cancer. Accessed 2026-06-10.

Metastatic non-small cell lung cancer full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing